California State Teachers Retirement System Trims Stock Position in Insulet Corporation $PODD

California State Teachers Retirement System lessened its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 8.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,647 shares of the medical instruments supplier's stock after selling 8,355 shares during the quarter. California State Teachers Retirement System owned 0.14% of Insulet worth $14,562,256 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. BlackRock Inc. purchased a new position in Insulet in the second quarter valued at approximately $1,018,582,000. Norges Bank acquired a new position in Insulet during the 4th quarter worth $300,794,000. Arrowstreet Capital Limited Partnership grew its position in shares of Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the period. Man Group plc acquired a new position in shares of Insulet during the 2nd quarter worth about $78,746,000. Finally, Bank of America Corp DE bought a new stake in shares of Insulet during the 2nd quarter valued at $64,921,000.

Insulet Stock Up 0.7%

PODD traded up $0.90 during trading hours on Tuesday, hitting $138.70. 695,972 shares of the company's stock were exchanged, compared to its average volume of 1,364,864. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88. The stock's 50-day moving average is $151.92 and its two-hundred day moving average is $172.63. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The stock has a market cap of $9.62 billion, a price-to-earnings ratio of 25.95, a PEG ratio of 1.04 and a beta of 1.08.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating analysts' consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company's quarterly revenue was up 23.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Sell-side analysts predict that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on PODD. William Blair initiated coverage on shares of Insulet in a report on Wednesday, May 20th. They issued an "outperform" rating on the stock. Truist Financial reissued a "hold" rating and issued a $153.00 target price (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Leerink Partners lowered Insulet from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $247.00 to $145.00 in a research report on Thursday, August 6th. Sanford C. Bernstein dropped their target price on Insulet from $200.00 to $175.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Finally, Robert W. Baird set a $175.00 price objective on Insulet in a report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Insulet currently has an average rating of "Hold" and a consensus price target of $195.40.

Insulet Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.